These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 24840727)

  • 1. Highlights of topic "Biochemical and molecular pathological aspects of cholangiocarcinoma".
    Murakami Y
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):359-61. PubMed ID: 24840727
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular aspects of cholangiocarcinoma.
    Kiguchi K
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):371-9. PubMed ID: 24420749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholangiocarcinoma.
    Krasinskas AM
    Surg Pathol Clin; 2018 Jun; 11(2):403-429. PubMed ID: 29751883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
    Braconi C; Roessler S; Kruk B; Lammert F; Krawczyk M; Andersen JB
    Liver Int; 2019 May; 39 Suppl 1():32-42. PubMed ID: 30829432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
    Borad MJ; Gores GJ; Roberts LR
    Curr Opin Gastroenterol; 2015 May; 31(3):264-8. PubMed ID: 25763789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.
    Jensen LH; Jakobsen A
    Expert Rev Anticancer Ther; 2011 Apr; 11(4):589-600. PubMed ID: 21504326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-specific marker genes for intrahepatic cholangiocarcinoma: utility and mechanistic insight.
    Blechacz B; Gores GJ
    J Hepatol; 2008 Aug; 49(2):160-2. PubMed ID: 18538440
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.
    Voss JS; Holtegaard LM; Kerr SE; Fritcher EG; Roberts LR; Gores GJ; Zhang J; Highsmith WE; Halling KC; Kipp BR
    Hum Pathol; 2013 Jul; 44(7):1216-22. PubMed ID: 23391413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential targeted therapy for liver fluke associated cholangiocarcinoma.
    Vaeteewoottacharn K; Seubwai W; Bhudhisawasdi V; Okada S; Wongkham S
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):362-70. PubMed ID: 24408866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical presentation and management of intrahepatic cholangiocarcinoma.
    Farges O; Fuks D
    Gastroenterol Clin Biol; 2010 Mar; 34(3):191-9. PubMed ID: 20202770
    [No Abstract]   [Full Text] [Related]  

  • 11. Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma.
    Chung V
    Surg Oncol Clin N Am; 2015 Jan; 24(1):187-98. PubMed ID: 25444475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photodynamic therapy of cholangiocarcinoma cancer.
    Ortner MA
    Gastrointest Endosc Clin N Am; 2000 Jul; 10(3):481-6. PubMed ID: 10899258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.
    Oliveira DV; Zhang S; Chen X; Calvisi DF; Andersen JB
    Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):349-356. PubMed ID: 28162004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholangiocarcinoma: molecular pathways and therapeutic opportunities.
    Ilyas SI; Borad MJ; Patel T; Gores GJ
    Semin Liver Dis; 2014 Nov; 34(4):456-64. PubMed ID: 25369307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABCB4/MDR3 gene mutations and cholangiocarcinomas.
    Tougeron D; Fotsing G; Barbu V; Beauchant M
    J Hepatol; 2012 Aug; 57(2):467-8. PubMed ID: 22387667
    [No Abstract]   [Full Text] [Related]  

  • 16. p53 Mutations in human cholangiocarcinoma: a review.
    Khan SA; Thomas HC; Toledano MB; Cox IJ; Taylor-Robinson SD
    Liver Int; 2005 Aug; 25(4):704-16. PubMed ID: 15998419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to move to targeted drugs in biliary tract cancer?
    Louvet C; Tournigand C
    Onkologie; 2010; 33(1-2):10-1. PubMed ID: 20164655
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeted sequencing and molecular profiling of a papillary and cribriform clear cell intrahepatic cholangiocarcinoma reveals absence of selectable mutations.
    Aldecoa I; Montironi C; Vargas GM; Nunes DA; Miquel R; Cuatrecasas M
    Gastroenterol Hepatol; 2019; 42(6):374-375. PubMed ID: 30293915
    [No Abstract]   [Full Text] [Related]  

  • 19. Difference in biological characteristics and sensitivity to chemotherapy and radiotherapy between intrahepatic and extrahepatic cholangiocarcinoma cells in vitro.
    He XR; Wu XP
    Chin Med Sci J; 2008 Mar; 23(1):54-9. PubMed ID: 18437912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetics of hepatobiliary carcinogenesis.
    Nault JC; Zucman-Rossi J
    Semin Liver Dis; 2011 May; 31(2):173-87. PubMed ID: 21538283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.